Background: We aimed to identify a human immunodeficiency virus (HIV)-related microbiota signature, independent of sexual preferences and demographic confounders, in order to assess a possible impact of the microbiome on metabolic comorbid conditions.
Methods: Bacterial 16S ribosomal RNA analyses were performed on stool samples from 405 HIV-infected and 111 uninfected participants of the Copenhagen Comorbidity in HIV Infection (COCOMO) study. Individuals were stratified according to sexual behavior (men who have sex with men [MSM] vs non-MSM).
Results: After excluding MSM-associated microbiota traits and adjusting for confounders, we identified an HIV-related microbiota signature, consisting of lower biodiversity, increased relative abundance of the bacterial clades Gammaproteobacteria and Desulfovibrionaceae and decrease in several Clostridia. This microbiota profile was associated with a 2-fold excess risk of metabolic syndrome, driven by increase in Desulfovibrionaceae and decrease in Clostridia (Butyrivibrio, Coprococcus 2, Lachnospiraceae UCG-001 and CAG-56). This association was accentuated (5-fold excess risk) in individuals with previous severe immunodeficiency, which also modified the association between HIV-related microbiota signature and visceral adipose tissue (VAT) area (P for interaction = .01). Accordingly, HIV-related microbiota was associated with 30-cm2 larger VAT in individuals with history of severe immunodeficiency, but not in those without.
Conclusion: The HIV-related microbiota was associated with increased risk of metabolic syndrome and VAT accumulation, particularly in individuals with previous severe immunodeficiency, driven by increased Desulfovibrionaceae and lower abundance of several Clostridia. Our findings suggest a potential interplay between HIV-related microbiota, immune dysfunction and metabolic comorbid conditions. Interventions targeting the gut microbiome may be warranted to reduce cardiovascular risk, particularly in individuals with previous immunodeficiency.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciz1235 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of HIV antiretroviral therapy on gut microbiota: the need for well-designed longitudinal studies.
J Infect Dev Ctries
October 2024
University Clinical Research Center (UCRC), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Introduction: Human immunodeficiency virus (HIV) infection remains a major public health concern despite a significant decline in HIV-related mortality and morbidity. These significant advances are linked mostly to effective antiretroviral therapy (ART). However, these treatments are not without consequences on other microorganisms in our body, especially when they must be used for life.
View Article and Find Full Text PDFModulating Immune Responses: The Double-Edged Sword of Platelet CD40L.
Semin Thromb Hemost
October 2024
Department of Pharmacy, University of Bonn, Bonn, Germany.
Article Synopsis
- The CD40-CD40L interaction is crucial for regulating the immune system, affecting monocytes, T cells, and B cells, as well as antibody production.
- While traditionally linked to immune cells, activated platelets express most CD40L, playing a key role in communications with immune cells and helping to fight infections.
- However, CD40L can also contribute to harmful inflammation in conditions like HIV and sepsis, making it a double-edged sword; thus, targeting CD40L for treating inflammatory diseases requires careful consideration to avoid severe side effects.
Pulmonary comorbidities in people with HIV- the microbiome connection.
Curr Opin HIV AIDS
September 2024
Institute of Clinical Medicine, University of Oslo.
Purpose Of Review: To report recent evidence on associations between human microbiome, particularly airway and gut, and pulmonary comorbidities in people with HIV (PWH). Furthermore, we explore how changes in the microbiome may contribute to pulmonary immune dysregulation and higher rates of pulmonary comorbidities among PWH. Finally, we propose future directions in the field.
View Article and Find Full Text PDFGut microbiome and cardiometabolic comorbidities in people living with HIV.
Microbiome
June 2024
Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Article Synopsis
- People living with HIV (PLWH) face a higher risk of inflammatory-driven comorbidities like cardiovascular disease (CVD), potentially influenced by changes in the gut microbiome and other factors.
- Research indicates that PLWH experience alterations in their gut microbiome, which may contribute to cardiometabolic issues, showing similar features to microbiota linked with CVD and reduced production of beneficial short-chain fatty acids (SCFAs).
- While recent findings offer insights into the relationship between the gut microbiome, metabolites, and comorbidities in PLWH, these factors are not currently recognized as reliable biomarkers or therapeutic targets, highlighting the need for further research in clinical applications.
Gut resistome linked to sexual preference and HIV infection.
BMC Microbiol
June 2024
IrsiCaixa, Ctra de Canyet S/N, 08916, Badalona, Spain.
Background: People living with HIV (PLWH) are at increased risk of acquisition of multidrug resistant organisms due to higher rates of predisposing factors. The gut microbiome is the main reservoir of the collection of antimicrobial resistance determinants known as the gut resistome. In PLWH, changes in gut microbiome have been linked to immune activation and HIV-1 associated complications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!